Original article by Jared Lynch
The Australian – Page: 15 : 19-Jul-21
Brisbane-based biotechnology firm Ellume has secured approval from the US Food & Drug Administration to sell its COVID-19 tests to point-of-care providers. The approval came three months after the FDA approved Ellume’s over-the-counter tests, which Australian laws currently ban. Only point-of-care providers are allowed to administer COVID-19 tests in Australia, and Ellume CEO Sean Parsons considers the local point-of-care market to be a small one. Ellume secured a $US235 million ($316 million) contract in February from the US Department of Defense for the rollout of its rapid COVID-19 test, while it is building a factory in the state of Maryland.
ELLUME LIMITED, UNITED STATES. FOOD AND DRUG ADMINISTRATION